Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology Inc (CRDF) is a clinical-stage biotech company advancing novel therapies targeting cancers with high unmet need through its focus on PLK1 inhibition. This page provides investors and researchers with timely updates on clinical developments, strategic initiatives, and scientific breakthroughs driving the company's precision oncology pipeline.
Access the latest CRDF news including trial updates for RAS-mutated mCRC and other challenging cancers, partnership announcements, and regulatory milestones. Our curated collection features press releases on onvansertib developments, peer-reviewed data highlights, and management commentary to inform your analysis of this innovative oncology player.
Key content categories include Phase 2 trial progress updates, scientific conference presentations, and operational developments shaping Cardiff's therapeutic pipeline. Bookmark this page for streamlined tracking of CRDF's efforts to transform cancer treatment through mechanism-driven approaches.
Cardiff Oncology (Nasdaq: CRDF) announced the dosing of the first patient in its Phase 2 ONSEMBLE trial of onvansertib, aimed at treating KRAS/NRAS-mutated metastatic colorectal cancer (mCRC). This trial seeks to demonstrate a significant improvement in treatment response when combining onvansertib with the standard of care, FOLFIRI/bevacizumab. The primary endpoint focuses on objective response rates, while secondary endpoints include progression-free survival and overall survival. The trial is being conducted at nearly half of the planned 40 sites in the U.S., showing strong interest from investigators.
Cardiff Oncology (Nasdaq: CRDF) announced the formal introduction of its Scientific Advisory Board (SAB) on March 6, 2023. The SAB consists of esteemed leaders in oncology drug development and will guide the advancement of onvansertib, the company's lead asset targeting various cancers, including metastatic colorectal and pancreatic cancers. Notable members include Dr. Scott Kopetz and Dr. Heinz-Josef Lenz, among others, who bring extensive expertise in clinical research. The SAB is expected to expand its membership to enhance expertise in new clinical indications, reinforcing Cardiff's commitment to improving cancer treatment options.
FAQ
What is the current stock price of Cardiff Oncology (CRDF)?
What is the market cap of Cardiff Oncology (CRDF)?
